Last reviewed · How we verify
meningococcal B rLP2086 vaccine candidate — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
meningococcal B rLP2086 vaccine candidate (meningococcal B rLP2086 vaccine candidate) — Wyeth is now a wholly owned subsidiary of Pfizer.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| meningococcal B rLP2086 vaccine candidate TARGET | meningococcal B rLP2086 vaccine candidate | Wyeth is now a wholly owned subsidiary of Pfizer | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- meningococcal B rLP2086 vaccine candidate CI watch — RSS
- meningococcal B rLP2086 vaccine candidate CI watch — Atom
- meningococcal B rLP2086 vaccine candidate CI watch — JSON
- meningococcal B rLP2086 vaccine candidate alone — RSS
Cite this brief
Drug Landscape (2026). meningococcal B rLP2086 vaccine candidate — Competitive Intelligence Brief. https://druglandscape.com/ci/meningococcal-b-rlp2086-vaccine-candidate. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab